Better PrEParation for HIV prevention in minority groups

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY Nature Reviews Urology Pub Date : 2024-12-06 DOI:10.1038/s41585-024-00981-w

Louise Lloyd

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

加强对少数群体艾滋病毒预防的准备

在一项III期、双盲、随机、主动对照试验中，每26周接受每年两次皮下lenacapavir作为暴露前预防（PrEP），可显著降低顺性男性、变性女性、变性男性和性别非二元者的HIV发病率。在纳入的3265名参与者中，lenacapavir组中有2人被诊断为HIV（每100人年0.10人），而每日口服恩曲西他滨-替诺福韦双氧吡酯富马酸酯的有9人（0.93人/ 100人年），背景发病率为2.37人/ 100人年。没有发现安全隐患。因此，这种治疗方案对这些高危人群有希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.